pamidronate has been researched along with tiludronic acid in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Licata, AA | 1 |
| Fleisch, HA | 1 |
| Kautiainen, S; Luurila, S; Ylitalo, P; Ylitalo, R | 2 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Papapoulos, SE | 1 |
| Watts, NB | 1 |
| Epstein, M; Joshua, F; Major, G | 1 |
| Donáth, J; Fornet, B; Gergely, P; Krasznai, M; Poór, G | 1 |
| Boos, J; Lanvers-Kaminsky, C; Vorotnjak, M | 1 |
| Khuri, F; Saba, N | 1 |
| Orcel, P; Rousière, M | 1 |
| Silverman, SL | 1 |
| Byard, S; Duer, MJ; Ironside, MS; Reid, DG | 1 |
9 review(s) available for pamidronate and tiludronic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Bisphosphonate therapy.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoclasts; Osteoporosis; Osteoporosis, Postmenopausal; Pamidronate; Risedronic Acid | 1997 |
Bisphosphonates: preclinical aspects and use in osteoporosis.
Topics: Alendronate; Animals; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Osteoporosis; Pamidronate | 1997 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
Topics: Administration, Oral; Alendronate; Animals; Bone and Bones; Bone Density; Calcium Channel Blockers; Controlled Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Pamidronate; Papio; Prospective Studies; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Time Factors | 2000 |
Treatment of osteoporosis with bisphosphonates.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Risedronic Acid | 2001 |
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clodronic Acid; Diphosphonates; Etidronic Acid; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Ibandronic Acid; Imidazoles; Lung Neoplasms; Pamidronate; Positron-Emission Tomography; Predictive Value of Tests; Therapeutic Equivalency; Zoledronic Acid | 2005 |
[Paget's disease and its therapeutic management].
Topics: Administration, Oral; Alkaline Phosphatase; Biomarkers; Diphosphonates; Etidronic Acid; Follow-Up Studies; Humans; Infusions, Intravenous; Osteitis Deformans; Pamidronate; Remission Induction; Risedronic Acid; Time Factors; Treatment Outcome | 2005 |
Paget disease of bone: therapeutic options.
Topics: Alendronate; Alkaline Phosphatase; Anti-Inflammatory Agents; Diphosphonates; Etidronic Acid; Humans; Osteitis Deformans; Pamidronate; Retreatment; Risedronic Acid; Treatment Outcome | 2008 |
2 trial(s) available for pamidronate and tiludronic acid
| Article | Year |
|---|---|
Bisphosphonate resistance in Paget's disease of bone.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Anti-Inflammatory Agents; Clodronic Acid; Diphosphonates; Drug Resistance; Humans; Injections, Intravenous; Middle Aged; Osteitis Deformans; Pamidronate | 2003 |
Effect of bisphosphonate treatment in patients with Paget's disease of the skull.
Topics: Aged; Aged, 80 and over; Audiometry; Diphosphonates; Female; Follow-Up Studies; Hearing Loss, Sensorineural; Humans; Male; Middle Aged; Osteitis Deformans; Pamidronate; Statistics, Nonparametric; Temporal Bone; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
4 other study(ies) available for pamidronate and tiludronic acid
| Article | Year |
|---|---|
Transformation of bisphosphonates into insoluble material in human blood in vitro.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Biotransformation; Carbon Radioisotopes; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Humans; In Vitro Techniques; Male; Pamidronate | 1998 |
Pharmacokinetics of bisphosphonates in rabbits.
Topics: Animals; Clodronic Acid; Diphosphonates; Etidronic Acid; Male; Pamidronate; Rabbits; Tissue Distribution | 1999 |
In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.
Topics: Alendronate; Apoptosis; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Diphosphonates; Drug Screening Assays, Antitumor; Germany; Humans; Ibandronic Acid; Imidazoles; Neuroblastoma; Pamidronate; Time Factors; Zoledronic Acid | 2004 |
Bisphosphonate protonation states, conformations, and dynamics on bone mineral probed by solid-state NMR without isotope enrichment.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Crystallization; Diphosphonates; Horses; Imidazoles; Magnetic Resonance Spectroscopy; Molecular Structure; Pamidronate; Structure-Activity Relationship; Technology, Pharmaceutical; Zoledronic Acid | 2010 |